Patient characteristics
| Characteristic . | Overall . | VTE event . |
|---|---|---|
| Cytotoxic chemotherapy* | ||
| No | 6759 (58%) | 402 (58%) |
| Yes | 4936 (42%) | 291 (42%) |
| Age at accession, median (IQR), y | 61 (52-70) | 63 (54-71) |
| Anticoagulant subclass | ||
| Dabigatran | 35 (0%) | 3 (0%) |
| Heparinoid | 135 (1%) | 11 (2%) |
| None | 10 925 (96%) | 645 (95%) |
| Vitamin K antagonist | 143 (1%) | 10 (1%) |
| Xa-direct oral anticoagulant | 178 (2%) | 7 (1%) |
| Metastatic disease | ||
| No | 3312 (28%) | 121 (17%) |
| Yes | 8383 (72%) | 572 (83%) |
| Tumor type | ||
| Bladder | 400 (3%) | 32 (5%) |
| Breast | 1690 (14%) | 40 (6%) |
| Colorectal | 1084 (9%) | 62 (9%) |
| Esophagogastric | 286 (2%) | 30 (4%) |
| Gynecologic | 696 (6%) | 51 (7%) |
| Head and neck | 327 (3%) | 10 (1%) |
| Hepatobiliary | 383 (3%) | 32 (5%) |
| High-grade glioma | 487 (4%) | 44 (6%) |
| Lung | 1978 (17%) | 161 (23%) |
| Melanoma | 470 (4%) | 27 (4%) |
| Other | 1894 (16%) | 87 (13%) |
| Pancreatic adenocarcinoma | 487 (4%) | 57 (8%) |
| Prostate adenocarcinoma | 761 (7%) | 24 (3%) |
| Renal | 325 (3%) | 9 (1%) |
| Soft tissue sarcoma | 427 (4%) | 27 (4%) |
| VTE before cancer diagnosis | ||
| No | 11 530 (99%) | 673 (97%) |
| Yes | 165 (1%) | 20 (3%) |
| Characteristic . | Overall . | VTE event . |
|---|---|---|
| Cytotoxic chemotherapy* | ||
| No | 6759 (58%) | 402 (58%) |
| Yes | 4936 (42%) | 291 (42%) |
| Age at accession, median (IQR), y | 61 (52-70) | 63 (54-71) |
| Anticoagulant subclass | ||
| Dabigatran | 35 (0%) | 3 (0%) |
| Heparinoid | 135 (1%) | 11 (2%) |
| None | 10 925 (96%) | 645 (95%) |
| Vitamin K antagonist | 143 (1%) | 10 (1%) |
| Xa-direct oral anticoagulant | 178 (2%) | 7 (1%) |
| Metastatic disease | ||
| No | 3312 (28%) | 121 (17%) |
| Yes | 8383 (72%) | 572 (83%) |
| Tumor type | ||
| Bladder | 400 (3%) | 32 (5%) |
| Breast | 1690 (14%) | 40 (6%) |
| Colorectal | 1084 (9%) | 62 (9%) |
| Esophagogastric | 286 (2%) | 30 (4%) |
| Gynecologic | 696 (6%) | 51 (7%) |
| Head and neck | 327 (3%) | 10 (1%) |
| Hepatobiliary | 383 (3%) | 32 (5%) |
| High-grade glioma | 487 (4%) | 44 (6%) |
| Lung | 1978 (17%) | 161 (23%) |
| Melanoma | 470 (4%) | 27 (4%) |
| Other | 1894 (16%) | 87 (13%) |
| Pancreatic adenocarcinoma | 487 (4%) | 57 (8%) |
| Prostate adenocarcinoma | 761 (7%) | 24 (3%) |
| Renal | 325 (3%) | 9 (1%) |
| Soft tissue sarcoma | 427 (4%) | 27 (4%) |
| VTE before cancer diagnosis | ||
| No | 11 530 (99%) | 673 (97%) |
| Yes | 165 (1%) | 20 (3%) |
IQR, interquartile range.
Cytotoxic chemotherapy anytime from day −30 to day 365 from accession date.